JP2022542323A5 - - Google Patents
Info
- Publication number
- JP2022542323A5 JP2022542323A5 JP2022506188A JP2022506188A JP2022542323A5 JP 2022542323 A5 JP2022542323 A5 JP 2022542323A5 JP 2022506188 A JP2022506188 A JP 2022506188A JP 2022506188 A JP2022506188 A JP 2022506188A JP 2022542323 A5 JP2022542323 A5 JP 2022542323A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- cells
- pharmaceutically acceptable
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880310P | 2019-07-30 | 2019-07-30 | |
| US62/880,310 | 2019-07-30 | ||
| PCT/US2020/043788 WO2021021761A1 (en) | 2019-07-30 | 2020-07-27 | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542323A JP2022542323A (ja) | 2022-09-30 |
| JP2022542323A5 true JP2022542323A5 (enExample) | 2023-08-04 |
| JP7605824B2 JP7605824B2 (ja) | 2024-12-24 |
Family
ID=72087192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506188A Active JP7605824B2 (ja) | 2019-07-30 | 2020-07-27 | Ｃｂｌ－ｂの阻害のための尿素、アミド、および置換されたヘテロアリール化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220387395A1 (enExample) |
| EP (1) | EP4003965A1 (enExample) |
| JP (1) | JP7605824B2 (enExample) |
| CN (1) | CN114450271B (enExample) |
| AU (1) | AU2020320195A1 (enExample) |
| CA (1) | CA3148769A1 (enExample) |
| MX (1) | MX2022001199A (enExample) |
| WO (1) | WO2021021761A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034140A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP4096667A4 (en) * | 2020-01-29 | 2024-03-06 | Foghorn Therapeutics Inc. | COMPOUNDS AND USES THEREOF |
| WO2022217123A2 (en) | 2021-04-08 | 2022-10-13 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds |
| EP4359381A4 (en) * | 2021-06-21 | 2025-04-30 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| CN113577265B (zh) * | 2021-08-04 | 2022-04-15 | 明济生物制药（北京）有限公司 | Til细胞及其制备方法以及在癌症治疗中的用途 |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| AU2022379959A1 (en) | 2021-11-05 | 2024-05-09 | Genentech, Inc. | Lactams as cbl-b inhibitors selective over c-cbl |
| TW202342013A (zh) * | 2022-02-10 | 2023-11-01 | 英屬開曼群島商百濟神州有限公司 | 雜環化合物、其組成物及用其進行治療之方法 |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| US20230414598A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| CA3261875A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| EP4558501A1 (en) * | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| KR20250050018A (ko) | 2022-08-16 | 2025-04-14 | 그렌마크 파머수티칼스 엘티디. | Cbl-b 저해제로서의 치환된 피리디논 화합물 |
| WO2024062363A1 (en) * | 2022-09-21 | 2024-03-28 | Glenmark Pharmaceuticals Ltd | Bicyclic heterocyclic compounds as cbl-b inhibitors |
| WO2024074977A1 (en) * | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| EP4653436A1 (en) | 2023-01-19 | 2025-11-26 | Guangzhou Yufan Nantu Biotechnologies Co., Ltd | Heterocyclic compounds, preparation method therefor and use thereof |
| WO2024231852A1 (en) * | 2023-05-08 | 2024-11-14 | Glenmark Pharmaceuticals Ltd | Substituted biphenyl compounds as cbl-b inhibitors |
| WO2025067468A1 (en) * | 2023-09-28 | 2025-04-03 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| US20070054355A1 (en) * | 2003-03-05 | 2007-03-08 | Yuval Reiss | Cbl-b polypeptides, complexes and related methods |
| EP1614676A4 (en) * | 2003-03-27 | 2009-03-25 | Kirin Pharma Kk | CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF |
| WO2008033403A2 (en) * | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| AT506041A1 (de) * | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| ES2666746T3 (es) | 2010-07-13 | 2018-05-07 | Anthrogenesis Corporation | Métodos para generar linfocitos citolíticos naturales |
| EP2471548A1 (de) * | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| CA2946312A1 (en) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| AU2016297362B2 (en) * | 2015-07-17 | 2020-04-16 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as HDAC inhibitors |
| EP3138905A1 (en) | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| EP4212547A1 (en) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| CN107848953B (zh) | 2015-12-25 | 2021-05-18 | 四川海思科制药有限公司 | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
| EP3743063A4 (en) * | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
-
2020
- 2020-07-27 AU AU2020320195A patent/AU2020320195A1/en not_active Abandoned
- 2020-07-27 CA CA3148769A patent/CA3148769A1/en active Pending
- 2020-07-27 JP JP2022506188A patent/JP7605824B2/ja active Active
- 2020-07-27 EP EP20757062.3A patent/EP4003965A1/en active Pending
- 2020-07-27 US US17/631,886 patent/US20220387395A1/en active Pending
- 2020-07-27 WO PCT/US2020/043788 patent/WO2021021761A1/en not_active Ceased
- 2020-07-27 CN CN202080068222.0A patent/CN114450271B/zh active Active
- 2020-07-27 MX MX2022001199A patent/MX2022001199A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542323A5 (enExample) | ||
| JP2022532247A5 (enExample) | ||
| JP2022526025A5 (enExample) | ||
| JP2022538174A5 (enExample) | ||
| US12209102B2 (en) | Heterocyclic compounds and uses thereof | |
| US12485144B2 (en) | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | |
| US20230248733A1 (en) | Highly active anti-neoplastic and anti-proliferative agents | |
| US20230303702A1 (en) | Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen | |
| JP7062792B2 (ja) | Ｐｄ－１／ｐｄ－ｌ１阻害剤 | |
| JP7685821B2 (ja) | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 | |
| JP2023551355A (ja) | 抗腫瘍化合物並びにその調製方法及び使用 | |
| TWI767915B (zh) | Ror-1與btk拮抗劑的組合 | |
| UA128792C2 (uk) | ПОХІДНІ ТЕТРАГІДРО-1Н-ЦИКЛОПЕНТА[cd]ІНДЕНУ ЯК ІНГІБІТОРИ ФАКТОРА-2(АЛЬФА), ЩО ІНДУКУЄТЬСЯ ГІПОКСІЄЮ | |
| EP4132529A1 (en) | Compounds and uses thereof | |
| AU2015362089B2 (en) | Dislodgement and release of HSC using alpha 9 integrin antagonist and CXCR4 antagonist | |
| RS57481B1 (sr) | Pirazolopirimidinska jedinjenja | |
| TW202523326A (zh) | 雜環及其用途 | |
| JP2018535216A (ja) | アクリル酸誘導体、製造方法、および医薬としてのその使用 | |
| EA031243B1 (ru) | Ингибиторы серин/треонинкиназ | |
| CA3267008A1 (en) | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | |
| KR20060089215A (ko) | 항암제로서의 5-아릴피리미딘 | |
| CN107635553A (zh) | 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用 | |
| KR20230104125A (ko) | 헤테로아릴 헤테로사이클릭 화합물 및 이의 용도 | |
| AU2017326029A1 (en) | Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof | |
| CN121752560A (zh) | 经取代的苯基氧代噁唑基哌啶二酮化合物 |